Search Results - subject:"Drug reimbursement"

Does drug price-regulation affect healthcare expenditures?

Ben-Aharon, Omer; Shavit, Oren; Magnezi, Racheli - In: The European journal of health economics : HEPAC ; … 18 (2017) 7, pp. 859-867

Persistent link: https://www.econbiz.de/10011869108

The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions

Bognar, Katalin; Romley, John A.; Bae, Jay P.; Murray, James - In: Journal of health economics 51 (2017), pp. 1-12

Persistent link: https://www.econbiz.de/10011740630

Governance of conditional reimbursement practices in the Netherlands

Boon, Wouter; Martins, Luis; Koopmanschap, Marc - In: Health Policy 119 (2015) 2, pp. 180-185

When entering the market, orphan drugs are associated with substantial prices and a high degree of uncertainty regarding safety and effectiveness. This makes decision making about the reimbursement of these drugs a complex exercise. To advance on this, the Dutch government introduced a...

Persistent link: https://www.econbiz.de/10011190139

A comparative study of the role of disease severity in drug reimbursement decision making in four European countries

Franken, Margreet; Stolk, Elly; Scharringhausen, Tessa; … - In: Health Policy 119 (2015) 2, pp. 195-202

disease severity in drug reimbursement decision making in Belgium, France, The Netherlands and Sweden. We investigated … involved in drug reimbursement. Disease severity is an important consideration, especially where the level is high. The …. Although disease severity is important in drug reimbursement decision making in all four countries, all seem to struggle in …

Persistent link: https://www.econbiz.de/10011190143

Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: An interrupted time series study

Hsu, Jason C.; Lu, Christine Y.; Wagner, Anita K.; … - In: Health Policy 116 (2014) 2, pp. 196-205

To control increasing pharmaceutical expenditures, Taiwan's National Health Insurance has implemented a series of drug … reimbursement price reductions since 2000. This study examined changes in use and expenditures of oral antidiabetic medications …

Persistent link: https://www.econbiz.de/10010776766

Orphan drugs policies: a suitable case for treatment

Drummond, Michael; Towse, Adrian - In: The European Journal of Health Economics 15 (2014) 4, pp. 335-340

Without changes in the current policies, pharmaceutical companies will eventually cease responding to the incentives to develop orphan drugs, because they will increasingly be uncertain whether the drugs, if developed, will be reimbursed. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10010993990

Orphan drugs policies : a suitable case for treatment ; editorial

Drummond, Michael F.; Towse, Adrian - In: The European journal of health economics : HEPAC ; … 15 (2014) 4, pp. 335-340

Persistent link: https://www.econbiz.de/10010360871

Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis

Fischer, Katharina E.; Rogowski, Wolf H.; Leidl, Reiner; … - In: Health Policy 112 (2013) 3, pp. 187-196

The aim of this study was to analyze influences of process- and technology-related characteristics on the outcomes of coverage decisions. Using survey data on 77 decisions from 13 countries, we examined whether outcomes differ by 14 variables that describe components of decision-making processes...

Persistent link: https://www.econbiz.de/10011048364

Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time

Sandmann, Frank G.; Franken, Margreet G.; Steenhoek, Adri; … - In: Health Policy 112 (2013) 3, pp. 285-296

To investigate the desirability and feasibility of a cyclic reimbursement process to address uncertainty accompanying initial decision making.

Persistent link: https://www.econbiz.de/10010719299

The politics of health technology assessment in Poland

Ozieranski, Piotr; McKee, Martin; King, Lawrence - In: Health Policy 108 (2012) 2, pp. 178-193

First, to identify risks associated with the scientific evaluation of drugs considered for state reimbursement in Poland through exploring strategies of influence employed by multinational drug companies in relation to the Agency for Health Technology Assessment (AHTAPol). Second, to ascertain...

Persistent link: https://www.econbiz.de/10010594647